Voyager Therapeutics (VYGR) Price & Analysis

Compare

1,325 Followers

VYGR Stock Chart & Stats

$4.15

-$0.14(-2.36%)

At close: Jan 08 4:00 PM EST

$4.15

-$0.14(-2.36%)

Day’s Range― - ―

52-Week Range$2.65 - $5.55

Previous CloseN/A

Volume91.62K

Average Volume (3M)555.04K

Market Cap

$230.74M

Enterprise Value$223.15M

Total Cash (Recent Filing)$208.93M

Total Debt (Recent Filing)$38.37M

Price to Earnings (P/E)―

Beta1.34

Next Earnings

Mar 10, 2026

EPS Estimate

-0.51

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.47

Shares Outstanding55,600,082

10 Day Avg. Volume458,729

30 Day Avg. Volume555,037

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)1.09

Price to Sales (P/S)4.09

P/FCF Ratio-17.36

Enterprise Value/Market Cap0.97

Enterprise Value/Revenue7.13

Enterprise Value/Gross Profit7.13

Enterprise Value/Ebitda-1.67

Forecast

1Y Price Target

$15.33

Price Target Upside269.40% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)-1.6

Revenue Forecast (FY)$61.03M

Bulls Say, Bears Say

Bulls Say

Gene Therapy StrategyA one-time intravenous gene therapy designed to suppress intracellular tau may provide deep and durable target engagement and broaden therapeutic reach beyond extracellular antibody approaches, enhancing long-term value potential.

Imaging Proof Of ConceptA favorable tau imaging readout demonstrating measurable target engagement beyond prior antibody efforts would validate the scientific approach and could improve market perception of the program's prospects.

Pipeline DiversificationMultiple independent development programs spanning tau targeting, brain-shuttle delivery, and capsid platforms increase the likelihood that at least one approach achieves meaningful clinical progress, which could strengthen investor confidence.

Bears Say

Data Transparency ConcernsLimited published data and sparse trial analysis from peer programs leave critical scientific and safety questions unresolved, increasing perceived development risk for the field.

Key Opinion Leader SkepticismPersistent skepticism among key opinion leaders about the clinical effectiveness of tau antibodies undermines confidence in antibody-focused strategies and could slow broader adoption.

Peer Clinical FailureTermination of a major peer's tau antibody program after failing to meet statistical significance dampens investor expectations for the tau-targeting field and may pressure valuations.

Voyager Therapeutics News

Voyager Therapeutics Announces Chief Medical Officer Resignation

An announcement from Voyager Therapeutics ( ($VYGR) ) is now available. On February 9, 2026, Voyager Therapeutics, Inc....

19d ago

VYGR

Voyager Therapeutics Highlights 2026 CNS Pipeline and Strategy

Voyager Therapeutics ( ($VYGR) ) has issued an update. Voyager Therapeutics has posted a new corporate investor presentation...

2M ago

VYGR

Voyager Therapeutics price target lowered to $25 from $30 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Voyager Therapeutics (VYGR) to $25 from $30 and keeps a...

4M ago

VYGR

Voyager Therapeutics Reports Increased Losses Amid Rising R&D Costs

Voyager Therapeutics Inc. ( ($VYGR) ) has released its Q3 earnings. Here is a breakdown of the information...

4M ago

VYGR

Voyager Therapeutics: Strong Financial Position and Promising Pipeline Justify Buy Rating

TD Cowen analyst Phil Nadeau has maintained their bullish stance on VYGR stock, giving a Buy rating today....

4M ago

VYGR

Voyager Therapeutics files $400M mixed securities shelf

16:09 EST Voyager Therapeutics (VYGR) files $400M mixed securities shelf Published first on TheFly – the ultimate source...

4M ago

VYGR

Voyager Therapeutics price target lowered to $11 from $12 at Leerink

Leerink lowered the firm’s price target on Voyager Therapeutics (VYGR) to $11 from $12 and keeps an Outperform...

4M ago

VYGR

Voyager Therapeutics reports Q3 EPS (47c), consensus (52c)

Reports Q3 revenue $13.365M, consensus $7.86M. “Voyager continues to seek out the optimal modalities for each neurotherapeutic target...

4M ago

VYGR

Voyager Therapeutics expects cash to fund operations into 2028

Voyager is committed to maintaining a strong balance sheet that supports the advancement and growth of its platform...

4M ago

VYGR

Voyager Therapeutics, Transition Bio entered into drug discovery collab

Transition Bio and Voyager Therapeutics (VYGR) have entered into a drug discovery collaboration and license option agreement. The...

4M ago

VYGR

Voyager Therapeutics Advances Alzheimer’s Study with VY7523

Voyager Therapeutics Inc. (($VYGR)) announced an update on their ongoing clinical study. Voyager Therapeutics Inc. is conducting a...

4M ago

VYGR

Voyager Therapeutics: Strategic Positioning and Regulatory Endorsements Drive Buy Rating

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Voyager Therapeutics, retaining the price target of...

5M ago

VYGR

Voyager Therapeutics: Promising Alzheimer’s Portfolio and Innovative NeuroShuttle Platform Justify Buy Rating

Voyager Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from...

6M ago

VYGR

3 ‘Strong Buy’ Biotech Stocks Top Analysts Believe Have Over 300% Upside

Wall Street analysts don’t hand out “Strong Buy” ratings lightly. When they do, it usually means they’re convinced...

6M ago

CGEM

TECX

VYGR FAQ

What was Voyager Therapeutics’s price range in the past 12 months?

Voyager Therapeutics lowest stock price was $2.65 and its highest was $5.55 in the past 12 months.

What is Voyager Therapeutics’s market cap?

Voyager Therapeutics’s market cap is $230.74M.

When is Voyager Therapeutics’s upcoming earnings report date?

Voyager Therapeutics’s upcoming earnings report date is Mar 10, 2026 which is in 7 days.

How were Voyager Therapeutics’s earnings last quarter?

Voyager Therapeutics released its earnings results on Nov 10, 2025. The company reported -$0.47 earnings per share for the quarter, beating the consensus estimate of -$0.521 by $0.051.

Is Voyager Therapeutics overvalued?

According to Wall Street analysts Voyager Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Voyager Therapeutics pay dividends?

Voyager Therapeutics does not currently pay dividends.

What is Voyager Therapeutics’s EPS estimate?

Voyager Therapeutics’s EPS estimate is -0.51.

How many shares outstanding does Voyager Therapeutics have?

Voyager Therapeutics has 55,600,082 shares outstanding.

What happened to Voyager Therapeutics’s price movement after its last earnings report?

Voyager Therapeutics reported an EPS of -$0.47 in its last earnings report, beating expectations of -$0.521. Following the earnings report the stock price went up 0.709%.

Which hedge fund is a major shareholder of Voyager Therapeutics?

Currently, no hedge funds are holding shares in VYGR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Voyager Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-46.09%

Trailing 12-Months

Asset Growth

-32.33%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Voyager Therapeutics

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Voyager Therapeutics (VYGR) Earnings & Revenues

Historic Earnings Reports

VYGR Stock 12 Month Forecast

Average Price Target

$15.33

▲(269.40% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","26":"$26","7.25":"$7.25","13.5":"$13.5","19.75":"$19.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,7.25,13.5,19.75,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4,5.615384615384615,7.230769230769231,8.846153846153847,10.461538461538462,12.076923076923077,13.692307692307693,15.307692307692308,16.923076923076923,18.53846153846154,20.153846153846153,21.76923076923077,23.384615384615387,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4,4.871538461538462,5.743076923076924,6.614615384615385,7.486153846153846,8.357692307692307,9.22923076923077,10.100769230769231,10.972307692307693,11.843846153846155,12.715384615384616,13.586923076923078,14.458461538461538,{"y":15.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4,4.461538461538462,4.923076923076923,5.384615384615385,5.846153846153847,6.307692307692308,6.769230769230769,7.230769230769231,7.6923076923076925,8.153846153846153,8.615384615384617,9.076923076923077,9.538461538461538,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.45,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.08,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.37,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.55,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.12,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.58,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.68,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.67,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.95,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.93,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >